Overview

Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)

Status:
Completed

Trial end date:
2017-12-06

Target enrollment:

Participant gender:

Summary

This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in subsequent cohorts. Randomized subjects will receive a fixed weekly dose of study drug or placebo for a 4 week dosing period.

Phase:

Phase 2

Details

Lead Sponsor:

PhaseBio Pharmaceuticals Inc.

Treatments:

VIP-ELP fusion molecule PB1046